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Doxorubicin (DOX) is an anthracycline antibiotic utilized in
antitumor therapy; however, its clinical use is frequently
impeded by renal toxic effects. As peroxisome proliferator-
activated receptor-a (PPAR-a) has renoprotective effects in
drug-related kidney injuries, we tested its ability to inhibit
DOX-induced renal injury. Although both male PPAR-a
knockout mice and their wild-type littermates (pure 129/SvJ
background) had significant proteinuria 4 weeks after DOX
treatment, those with deletion of PPAR-a had more severe
proteinuria. This was associated with more serious podocyte
foot process effacement compared with wild-type mice. In
contrast, the PPAR-a agonist fenofibrate effectively reduced
proteinuria and attenuated DOX-induced podocyte foot
process effacement. Consistently, glomerular nephrin
expression was significantly lower in the knockout compared
with wild-type mice following DOX treatment. Fenofibrate
therapy significantly blunted the reduction in glomerular
nephrin levels in DOX-treated wild-type mice. In cultured
podocytes, DOX induced apoptosis, increased cleaved
caspase-3 levels, and decreased Bcl-2 expression, all
attenuated by pretreatment with fenofibrate. Thus, PPAR-a
deficiency exacerbates DOX-related renal injury, in part, due
to increased podocyte apoptosis.
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Doxorubicin (DOX) is an anthracycline antibiotic used widely
in antitumor therapy; however, its clinical use can have a
cytotoxic effect on several organs, especially the kidney. The
toxic effects of doxorubicin on the renal structure are podocyte
foot process effacement and increased glomerular permeability,
leading to proteinuria.1–3 The mechanisms involved in DOX-
associated nephropathy remain incompletely understood.
Among many possible pathogenic factors, oxygen free radicals
have been thought to have a critical role.4,5 Because of this
incomplete understanding of underlying mechanisms, the
current therapies of DOX-associated nephropathy remain
suboptimal, and novel treatments are urgently needed.
Recently, a subfamily of the nuclear receptor transcription
factors, peroxisome proliferator-activated receptors (PPARs),
including PPAR-a, PPAR-b/d, and PPAR-g, has been
increasingly recognized as key players in the pathogenesis
of metabolic syndrome and its renal complications.6 PPAR-a,
as the first identified PPAR isoform, is a target for various
long-chain fatty acids and is predominantly expressed in
tissues exhibiting high catabolic rates of fatty acids, such as
adipose tissue, liver, heart, muscle, and renal cortex.7 The
actions of PPAR-a are mainly through a ligand-dependent
transactivation mechanism, by which PPAR-a heterodi-
merizes with retinoid X receptor-a and regulates the
transcriptional activity of its target genes by binding to the
PPAR response element (PPRE) located in the promoter
regions of PPAR-a target genes.8 PPAR-a is highly abundant
in the proximal tubules and medullary thick ascending limbs,
with lower levels in the glomeruli.9 In general, PPAR-a
controls a set of genes essential for fatty acid b-oxidation and
has an important role in the metabolic control of renal
energy homeostasis.10 Besides its role in regulating lipid
metabolic role, PPAR-a also shows anti-inflammatory and
antifibrotic effects by ligand-dependent transrepressing
actions on nuclear factor-kB and activator protein-1 path-
ways.11–14 The PPAR-a agonist fenofibrate significantly
attenuated but PPAR-a gene deficiency markedly worsened
albuminuria and glomerular fibrosis in type 2 diabetic db/db
mice.12,13 Recently, activation of PPAR-a by fibrate treatment
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was also shown to be effective in ameliorating cisplatin-
induced renal tubular injury15 and DOX-induced apoptosis
in renal tubular cells.16
Although PPAR-a exerts a renoprotective effect in many
renal disorders, whether PPAR-a is involved in the pathogen-
esis of DOX-associated podocyte injury is unclear. Thus, we
aimed to investigate the role of PPAR-a in DOX-induced
renal injury in vivo and in vitro and examine whether PPAR-a
activation could represent a preventive maneuver for DOX-
associated nephrotoxicity.
RESULTS
Proteinuria and podocyte foot process effacement in DOX-
treated wild-type (WT) and PPAR-a knockout mice on a pure
129/SvJ background
Following DOX treatment, both WT and PPAR-a/ mice on a
129/SvJ background showed significant albuminuria, with more
severe proteinuria and hypoalbuminemia in PPAR-a/ mice
than in WT mice (Figure 1). Consistently, DOX-treated PPAR-
a/ mice exhibited higher plasma cholesterol and triglyceride
levels than did WT mice (Table 1). Electron microscopy revealed
podocyte foot process effacement in both groups (Figure 2A). In
each photograph, the mean of the foot process width was
calculated as described in the Materials and Methods. As shown
in Figure 2B, DOX treatment resulted in more severe podocyte
foot process effacement in PPAR-a/ mice than in WT mice
on a 129/SvJ background (foot process width 2446±37.04 vs
854.4±30.94 nm, Po0.01).
Glomerular expression of nephrin in DOX-treated WT and
PPAR-a/ mice on a pure 129/SvJ background
The expression of nephrin in the glomeruli and the kidneys
was measured by immunohistochemistry and real-time
PCR (RT-PCR), respectively. As expected, strong glomer-
ular nephrin immunoreactivity was observed in WT mice
(Figure 3A). Although the expression of nephrin was
markedly decreased in the glomeruli of both DOX-treated
WT and PPAR-a/ mice, nephrin immunoreactivity was
significantly lower in PPAR-a/ than in WT mice after DOX
treatment (Figure 3A and B). RT-PCR analysis of renal
nephrin expression further showed that the levels of nephrin
mRNA expression was significantly lower in PPAR-a/ than
in WT mice after DOX treatment (Figure 3C).
Effect of PPAR-a agonist fenofibrate on proteinuria and
podocyte foot process effacement in DOX-treated WT mice
on both 129/SvJ and BALB/c backgrounds
Treatment with a PPAR-a agonist fenofibrate for 1 month
significantly reduced the level of DOX-induced proteinuria,
although the levels remained higher than that in controls
(Figure 4a). DOX-treated mice exhibited decreased plasma
albumin levels, with no significant difference in levels
between DOX and fenofibrate-treated mice (Figure 4b).
Plasma cholesterol and triglyceride levels showed a slight but
not significant increase in the DOX group (Table 2). Electron
microscopy revealed DOX-treated mice with more severe
podocyte foot process effacement than control mice, and
fenofibrate treatment significantly improved podocyte foot
process effacement induced by DOX (Figure 5).
We further verified the renoprotective role of PPAR-a in
DOX-induced renal injury in mice of a pure BALB/c
background. Consistent with the findings observed in 129/
SvJ mice, PPAR-a agonist fenofibrate significantly improved
DOX-associated nephropathy in BALB/c mice (Supplemen-
tary Figures S1–4 online). Fenofibrate treatment significantly
reduced proteinuria levels and attenuated podocyte foot
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Figure 1 |Changes in proteinuria (a) and plasma albumin (b) levels in doxorubicin (DOX)-treated wild-type (WT) and peroxisome
proliferator-activated receptor-a (PPAR-a) knockout mice. Data are means±s.e.m. *Po0.05, **Po0.01 vs WT; ##Po0.01 vs PPAR-a/;
þþPo0.01 vs WTþDOX, N¼ 5.
Table 1 |Metabolic and physiological parameters in DOX-treated WT and PPAR-a knockout mice
WT WT+DOX PPAR-a/ PPAR-a/+DOX
Body weight (g) 26.76±0.55 25.22±0.51 25.12±0.41 20.74±0.83**,##,++
Liver/body weight (%) 3.99±0.10 4.32±0.11 4.21±0.11 5.50±0.16**,##,++
Kidney/body weight (%) 0.69±0.01 0.65±0.02 0.65±0.03 0.60±0.02
Fat/body weight (%) 1.61±0.19 1.50±0.27 1.83±0.14 0.69±0.04**,##,++
Plasma cholesterol (mg/dl) 114.8±11.18 198.4±36.01 136.6±15.27 390.2±23.89**,##,++
Plasma triglyceride (mg/dl) 98.72±10.98 173.3±28.04 112.9±12.24 296.8±30.57**,##,++
Abbreviations: DOX, doxorubicin; PPAR-a, peroxisome proliferator-activated receptor-a; WT, wild type.
*Po0.01 vs WT; ##Po0.01 vs PPAR-a/; ++Po0.01 vs WT+DOX.
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process effacement (Supplementary Figure S1 online). Feno-
fibrate treatment also lowered blood urea nitrogen levels and
reduced urinary KIM-1 (kidney injury molecule-1) excretion
(Supplementary Figure S2 online). Glomeruloscelerosis and
tubulointerstitial fibrosis were markedly ameliorated after
fenofibrate treatment (Supplementary Figure S3 online).
Moreover, fenofibrate treatment significantly restored glome-
rular nephrin expression in DOX-treated BALB/c mice
(Supplementary Figure S4 online). Collectively, these
results confirm the findings in 129/SvJ mice and support
our conclusion that PPAR-a agonists represent potential
preventive agents for DOX-induced nephropathy.
Effect of fenofibrate on proteinuria and podocyte foot process
effacement in DOX-treated PPAR-a gene knockout mice
We examined the protective effect of fenofibrate on DOX-
induced renal injury in PPAR-a gene knockout mice
(Supplementary Figures S5–8 online). The results showed
that fenofibrate had little effect on proteinuria (Supplemen-
tary Figure S5A online), plasma albumin levels (Supplemen-
tary Figure S5B online), podocyte foot process effacement
(Supplementary Figure S5C and D online), blood urea
nitrogen and serum creatinine levels (Supplementary Figure
S6A and B online), urinary KIM-1 excretion (Supplementary
Figure S6C online), glomerular histology (Supplementary
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Figure 2 |Doxorubicin (DOX)-induced podocyte foot process effacement in peroxisome proliferator-activated receptor-a (PPAR-a)
wild-type (WT) and knockout mice. (a) Representative electron microscopy images of podocyte foot processes: (A) WT; (B) WT with DOX
(WTþDOX); (C) PPAR-a knockout (PPAR-a/); (D) PPAR-a knockout with DOX (PPAR-a/þDOX). (b) Quantification of foot process
effacement. Data are means±s.e.m. **Po0.01 vs WT; ##Po0.01 vs PPAR-a/; þþPo0.01 vs WTþDOX, N¼ 5.
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Figure 3 | Immunohistochemistry and quantitative real-time PCR analysis of nephrin expression in the glomeruli of wild-type (WT)
and peroxisome proliferator-activated receptor-a (PPAR-a) knockout mice receiving doxorubicin (DOX) treatment. Downregulated
expression of nephrin was observed in both DOX-treated WT and PPAR-a knockout mice. (a) Representative immunohistochemical
stainings for nephrin: (A) WT; (B) WT with DOX (WTþDOX); (C) PPAR-a knockout (PPAR-a/); and (D) PPAR-a knockout with DOX
(PPAR-a/þDOX). (b) Semiquantification of nephrin protein immunoreactivity in each group. (c) Real-time PCR assay confirmed
downregulated expression of nephrin in DOX-treated PPAR-a knockout mice. Data are means±s.e.m. *Po0.05, **Po0.01 vs WT;
#Po0.05, ##Po0.01 vs PPAR-a/; þPo0.05, þ þPo0.01 vs WTþDOX, N¼ 5.
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Figure S7 online), and nephrin expression (Supplementary
Figure S8 online) in PPAR-a knockout mice.
Effect of fenofibrate treatment on glomerular expression
of nephrin in mice receiving DOX treatment
The immunoreactivity of nephrin was markedly decreased in
glomeruli from DOX-treated mice on a pure 129/SvJ back-
ground, which was significantly improved by fenofibrate
treatment by immunohistochemistry (Figure 6A and B).
RT-PCR analysis further revealed that fenofibrate treatment
increased nephrin mRNA expression in DOX-treated mice
(Figure 6D). Immunofluorescence study demonstrated that
nephrin distribution was changed from a fine, linear-like to
discontinuous, coarse granular pattern in control mouse after
DOX treatment, which was attenuated by treatment with
fenofibrate (Figure 6C).These findings further support the
results of electron microscopy studies on podocytes shown in
Figures 2 and 5. Similarly, fenofibrate treatment also signifi-
cantly improved the DOX-induced decrease in nephrin
expression at both mRNA and protein levels in BALB/c mice
(Supplementary Figure S4 online).
PPAR-a expression in kidney, renal glomeruli, and cultured
podocytes
Although PPAR-a is abundantly expressed in the proximal
tubules and medullary thick ascending limbs, as assessed by in
situ hybridization9 and immunohistochemistry (Supplementary
Figure S9A online), low but functional PPAR-a expression was
also reported in glomerular cells including mesangial cells and
podocytes.6,8 Using RT-PCR, we found that PPAR-a was
constitutively expressed in freshly isolated mouse glomeruli
(Supplementary Figure S9B online). RT-PCR, western blot
analysis, and PPRE 3 luciferase reporter analysis further
revealed the presence of PPAR-a in podocytes. Both PPAR-a
mRNA and protein were detected in culture podocytes (Figure
7a). PPRE luciferase reporter analysis further demonstrated that
fenofibrate treatment significantly increased luciferase activity in
podocytes (Figure 7b), which suggests a functional expression of
PPAR-a in these cells. To test whether DOX suppression of
PPRE-Luc activity is specific to the PPAR-a pathway, we cultured
primary glomerular mesengial cells from PPAR-a knockout mice.
As shown in Supplementary Figure S10 online, DOX significantly
reduced PPRE-luciferase activity as seen in podocytes, and
fenofibrate treatment did not increase PPRE activity in PPAR-a-
deficient mesengial cells. It implies that DOX-suppressed PPRE-
luciferase activity may be shared among signaling cascades
downstream PPAR-b and/or PPAR-g.
Decreased PPAR-a expression in DOX-treated mouse kidneys
and cultured podocytes
Renal PPAR-a expression and localization was further analyzed
using RT-PCR and immunohistochemistry. DOX treatment
resulted in a significant reduction in PPAR-a mRNA and protein
levels in whole kidneys (Supplementary Figure S9A and C
online), with little effect on intrarenal localization of PPAR-a
protein (Supplementary Figure S9A online). Consistently, DOX-
treated podocytes exhibited reduced PPAR-a mRNA levels
(Supplementary Figure S9D online) and endogenous PPAR-a
activity (Figure 7b). As expected, PPAR-a expression was not
present in PPAR-a gene-deficient mice (Supplementary Figure
S9E online), and its level in podocytes was lower than in the
glomeruli and the kidneys (Supplementary Figure S9F online).
Interestingly, PPAR-a activation by fenofibrate treatment atte-
nuated the inhibitory effect of DOX on PPAR-a transcription
activity (Figure 7b). Fenofibrate treatment also increased
transcription of PPAR-a target genes CYP4A10 and CYP4A14,
although DOX-treated podocytes only slightly decreased the
expression of these genes (Figure 7c and d).
Fenofibrate treatment protected podocytes against
DOX-induced apoptosis
Fluorescence-activated cell sorting was performed to measure
apoptosis. Podocytes were stained with Annexin V–fluorescein
isothiocyanate and propidium iodide to distinguish viable,
apoptotic, and necrotic cells. As expected, DOX induced signifi-
cant apoptosis compared with untreated cells and fenofibrate
treatment significantly attenuated DOX-induced apoptosis.
Fenofibrate alone did not affect apoptosis in normal podocytes
(Figure 8a). These findings were further supported by a
significant reduction in DOX-induced glomerular cell apoptosis
after fenofibrate treatment (Supplementary Figure S11 online).
In line with these apoptotic changes, Bcl-2 (B-cell lymphoma 2)
mRNA expression was significantly decreased and Bax mRNA
expression increased in response to DOX treatment. However,
pretreatment with fenofibrate restored Bcl-2 and Bax expression
to control levels (Figure 8b). Consistently, protein expression of a
key downstream effector of apoptosis, cleaved caspase-3, was
significantly increased after DOX injury, whereas preincubation
with fenofibrate significantly ameliorated the increased caspase-3
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Figure 4 | The effect of fenofibrate treatment on (a) proteinuria
and (b) plasma albumin levels in doxorubicin (DOX)-treated
mice. Data are means±s.e.m. *Po0.05, **Po0.01 vs control (Con);
#Po0.05 vs DOX, N¼ 5.
Table 2 |Metabolic and physiological parameters in
DOX-treated mice with or without fenofibrate treatment
Con DOX Fib+DOX
Body weight (g) 25.95±1.05 24.35±0.33 23.78±0.49
Liver/body weight (%) 3.93±0.24 4.21±0.37 5.37±0.45*,#
Kidney/body weight (%) 0.69±0.03 0.67±0.03 0.66±0.02
Fat/body weight (%) 1.41±0.10 1.24±0.12 0.86±0.11*,#
Plasma cholesterol (mg/dl) 96.98±7.56 138.2±16.73 86.99±11.36
Plasma triglyceride (mg/dl) 83.94±12.49 116.3±21.74 80.42±12.95
Abbreviations: Con, control; DOX, doxorubicin; Fib, fenofibrate.
*Po0.05 vs Con; #Po0.05 vs DOX.
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activity (Figure 8c). It was also noticed that DOX treatment
resulted in a significant increase in reactive oxygen species
production, which was attenuated by treatment with fenofibrate
(Supplementary Figure S12 online).
Time course difference of DOX-associated nephropathy
between 129/SvJ and BALB/c mice
To determine whether mice on a 129/SvJ genetic background
behave similarly to BALB/c mice during the DOX experi-
ment, we performed a study characterizing the course of
DOX nephrotoxicity in both 129/SvJ and BALB/c strains. As
shown in Supplementary Figures S13–16 online, a 6-week
treatment of DOX continuously increased proteinuria levels
(Supplementary Figure S13A online) and decreased plasma
albumin concentrations (Supplementary Figure S13B online)
in 129/SvJ mice. Starting from week 4, podocyte foot process
effacement appeared and became more severe at week 6
(Supplementary Figure S13C and D online). Blood urea
nitrogen and urinary KIM-1 excretion were significantly
increased after 4 weeks of DOX treatment and became much
higher after 6 weeks of DOX exposure (Supplementary Figure
S14 online). Furthermore, podocyte nephrin expression was
much lower in the 6-week DOX-treated mice than in the 4-
week DOX-treated mice (Supplementary Figure S16 online).
Compared with BALB/c mice, in which glomerular sclerosis
and tubulointerstitial fibrosis became evident at week 4
(Supplementary Figure S3 online), 129/SvJ mice only
exhibited such changes 6 weeks after DOX treatment
(Supplementary Figure S15 online).
DISCUSSION
Increasing evidence suggests that PPAR-a may exert reno-
protective effect in the kidney.17–19 This study examined the
role of PPAR-a in DOX-induced podocyte injury in vivo and
in vitro. PPAR-a/ mice showed more severe urine protein
excretion and podocyte foot process effacement than WT
mice after DOX treatment. In contrast, fenofibrate treatment
effectively reduced proteinuria and ameliorated podocyte
foot process effacement in DOX-treated mice. In cultured
podocytes, fenofibrate protected against DOX-induced
apoptosis. These observations suggest that PPAR-a may
participate in the pathogenesis of DOX-induced glomerular
podocyte injury and represent a promising preventive target
for DOX-associated glomerulopathy.
Although PPAR-a activation exerts a beneficial renal effect
in DOX-associated renal injury, the underlying mechanisms
of how PPAR-a agonist protects against DOX-induced kidney
damage remain elusive. A study of diabetic nephropathy
showed that fenofibrate markedly attenuated albuminuria
and renal fibrosis in a murine model of type 2 diabetes
(db/db mice).13 In contrast, PPAR-a gene deficiency was
found to be associated with exacerbated diabetic nephrop-
athy, with more severe albuminuria and worsened renal
injury.12 In several tubular injury models, PPAR-a activa-
tion prevented cisplatin-induced renal tubular injury15 and
protected renal tubular cells against DOX-induced apop-
tosis16 and acute fatty acid toxicity.20 Our findings that
PPAR-a protects DOX-induced podocyte damage extend
previous observations of the fibrate class of PPAR-a agonists
conferring a renoprotective effect in type 2 diabetes21–23 and
cisplatin-induced nephropathy.15,24
In the present studies, we found that DOX treatment
significantly decreased PPAR-a expression in the kidneys
and cultured podocytes, suggesting that DOX-induced renal
injury may be associated with decreased PPAR-a activity.
In support of this, glomerular expression of nephrin was
much lower in PPAR-a/ mice than WT mice after DOX
treatment. After DOX treatment, the normal, fine linear
staining pattern of nephrin almost completely disappeared
and a discontinuous, coarse granular pattern was observed.
These observations suggest that PPAR-a gene deficiency was
associated with exacerbated DOX-associated podocyte
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Figure 5 | Fenofibrate treatment ameliorated podocyte foot process effacement in doxorubicin (DOX)-treated mice.
(a) Representative electron microscope images of podocyte foot processes: (A) control (Con); (B) DOX (DOX); and (C) fenofibrateþDOX
(FibþDOX). (b) Quantification of foot process effacement. Data are means±s.e.m. **Po0.01 vs Con; ##Po0.01 vs DOX, N¼ 5.
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damage and PPAR-a activation may be renoprotective in
DOX-treated mice. In fact, after treatment with fenofibrate,
DOX-induced downregulation and changes in expression
pattern of nephrin was significantly restored. These findings
are generally in agreement with a previous report in which
PPAR-a activation in podocytes caused an increased nephrin
expression by stimulating nephrin promoter activity and
reducing nephrin mRNA degradation.25 Therefore, it is
reasonable to postulate that PPAR-a agonist exerts a
renoprotective effect in DOX-induced renal injury, at least
in part, by increasing nephrin expression and maintaining
the integrity of podocytes.
A large amount of evidence suggests that genetic back-
ground has a strong influence on disease course and severity.
This study demonstrates that DOX can induce glomerular
sclerosis and tubulointerstitial fibrosis in both 129/SvJ and
BALB/c mice, with the latter being more susceptible.26,27
Although in 129/SvJ mice, tubulointerstitial fibrosis did not
occur until 6 weeks after DOX treatment, dysfunction of
renal tubules was evident at week 4. These observations
suggest that although it requires longer treatment for DOX to
induce glomerular sclerosis and tubulointerstitial fibrosis in
129/SvJ mice, they behave similarly to BALB/c mice after
DOX treatment. More importantly, PPAR-a agonist feno-
fibrate was effective in attenuating DOX-induced renal injury
in both 129/SvJ and BALB/c mice.
The podocyte is believed to be the site of the initial
injury in proteinuric renal diseases, including DOX-related
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Figure 6 | Immunohistochemistry, immunofluorescence, and quantitative real-time PCR analysis of nephrin expression in the
glomeruli of doxorubicin (DOX)-treated mice in the presence or absence of fenofibrate treatment. (a) Representative
immunostainings for nephrin by immunohistochemistry: (A) control (Con); (B) DOX (DOX); and (C) fenofibrateþDOX (FibþDOX).
(b) Semiquantification of nephrin protein immunoreactivity in each group. (c) Representative immunostainings for nephrin by
immunofluorescence: (A) in control mice, nephrin staining was detected as a fine, linear-like pattern along the glomerular capillary loop,
whereas in DOX-treated mice (B) the linear staining of nephrin disappeared completely, and a discontinuous, coarse granular pattern was
observed. After fenofibrate treatment (C) the changes were less serious than those in DOX-treated mice, and linear pattern of staining of
nephrin could be detected in most parts of the glomerular capillary wall. (d) Real-time PCR assay demonstrated that fenofibrate treatment
increased nephrin mRNA expression in DOX-treated mice. Data are means±s.e.m. *Po0.05, **Po0.01 vs Con; #Po0.05 vs DOX, N¼ 5.
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nephropathy. In this study, we found PPAR-a was constitu-
tively expressed in renal glomeruli and was functional in
cultured podocytes, and DOX treatment significantly reduced
its expression. The PPAR-a agonist fenofibrate protected
podocytes against DOX-induced apoptosis. This is consistent
with the finding that fenofibrate treatment significantly
reduced apoptotic cell numbers in the glomeruli of mice
treated with DOX. Therefore, the direct actions on podocytes
may represent a major mechanism involved in the renopro-
tective effect of fenofibrate in DOX-associated podocyte
injury.
Our finding of the PPAR-a agonist fenofibrate markedly
reducing DOX-induced apoptosis in cultured podocytes was
associated with increased antiapoptotic Bcl-2 expression,
decreased proapoptotic Bax expression, and reduced cleaved
caspase-3 levels. These findings suggest that PPAR-a may act
as an important protective factor in podocytes, and the
fibrate class of PPAR-a agonists may ameliorate DOX-
induced podocyte death and detachment via blocking the
apoptotic signal.
In the present studies, we demonstrated that activation of
PPAR-a confers protective effects in DOX-induced podocyte
injury in vitro and attenuates proteinuria, podocyte foot
effacement, and tubulointerstitial fibrosis in vivo. Fenofibrate
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Figure 7 |Peroxisome proliferator-activated receptor-a
(PPAR-a) expression and transcriptional activity in podocytes.
(a) Detection of PPAR-a mRNA and protein expression in culture
podocytes. (b) Ligand-induced transcriptional activity of PPAR-a.
Note that doxorubicin (DOX) reduced PPAR response element
(PPRE)-luciferase activity and fenofibrate treatment significantly
increased PPAR-a transcriptional activity in podocytes. (c) Real-
time PCR assay demonstrated that fenofibrate treatment
increased CYP4A10 mRNA expression in DOX-treated podocytes.
(d) Real-time PCR assay demonstrated that fenofibrate treatment
increased CYP4A14 mRNA expression in DOX-treated podocytes.
Data are means±s.e.m. *Po0.05 vs dimethylsulfoxide (DMSO);
#Po0.05, ##Po0.01 vs DOX, N¼ 3.
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treatment also shows a protective effect on tubular function
as reflected by a marked reduction in urinary KIM-1
excretion. However, we cannot rule out the possibility that
the role of PPARa in other glomerular cells and tubular cells
also contributes to beneficial effects of fenofibrate in DOX-
associated nephropathy, as it has been previously reported
that PPAR-a was functionally expressed in glomerular
mesangial cells, endothelial cells, and proximal tubule cells.6,8
The beneficial effect of fenofibrate on these cells may also
contribute to the renoprotective effect in DOX-treated mice.
Hyperlipidemia is one of the major features in DOX-
induced nephropathy.28,29 Our previous study demonstrated
that hyperlipidemia is associated with increased transcription
activity of SREBP-1 (sterol regulatory element binding
protein-1) and enhanced lipogenesis in the liver.30 Increasing
evidence suggests that hyperlipidemia and renal lipotoxicity
are important pathogenic factors in kidney damage,31,32 and
may contribute to the development and the progression of
DOX-associated nephropathy.
In summary, PPAR-a gene deficiency was associated with
exacerbated DOX nephropathy, with worsened proteinuria
due to podocyte injury. The PPAR-a agonist fenofibrate
was effective in ameliorating podocyte injury via main-
taining podocyte viability and integrity. The PPAR-a agonist
fenofibrate may represent a promising preventive agent in
treating DOX nephropathy.
MATERIALS AND METHODS
Animal treatment
Male PPAR-a knockout (PPAR-a/) mice and sex- and age-
matched WT littermates (8–10 weeks old, 22–28 g) on a pure 129/SvJ
background (Jackson Lab, Bar Harbor, ME) were used and approved
by the animal experimentation committee of Peking University Health
Science Center. To test the effect of PPAR-a gene deficiency on DOX
(doxorubicin hydrochloride; Sigma, St Louis, MO)-induced renal
damage, mice were divided into four groups of animals for
treatment: (1) WT; (2) WT mice treated with DOX (WTþDOX);
(3) PPAR-a knockout mice (PPAR-a/); and (4) PPAR-a knockout
mice treated with DOX (PPAR-a/þDOX). DOX was injected
intravenously twice on days 1 and 14 (10 mg/kg). An equivalent
volume of saline was injected into control groups. To test whether
PPAR-a activation attenuates DOX-associated kidney injury, WT
animals were assigned to three groups for treatment: (1) control
mice (Con); (2) mice treated with DOX (DOX); and (3) DOX-
treated mice fed a chow diet supplemented with 0.2% fenofibrate
(w/diet w; Sigma) for 7 days before DOX injection (FibþDOX).13
To measure 24-h proteinuria, mice were placed in individual mouse
metabolic cages (Tecniplast, Buguggiate, Italy) with free access to
water and food. At week 4, mice were killed, and their kidneys were
removed for examination by light and electron microscopy and
immunohistochemical and immunofluorescence study.
Biochemical measurement of blood and urine samples
Plasma concentrations of total cholesterol, triglycerides, and
albumin were measured using an autoanalyzer (Hitachi 7170A,
Tokyo, Japan). Urinary albumin excretion was assayed with a mouse
albumin enzyme-linked immunosorbent assay quantitation kit
(Bethyl, Montgomery, TX).
Electron microscopy and measurement of podocyte foot
process effacement
For electron microscopy examination, renal cortex samples were
minced into 1-mm3 pieces on ice, immediately fixed in 2.5%
buffered glutaraldehyde, and embedded in epoxy resin. Ultrathin
sections (0.1 mm thick) were examined by electron microscopy. To
study slit diaphragm morphology, random photographs were taken
at a final magnification of  10,000. Three glomeruli per mouse
were evaluated on five 10K images/glomerulus. Electron microscopy
images were analyzed using ImageJ (NIH Image, Bethesda, MD),
and the method of measuring podocyte foot process effacement was
adapted from a previous report.33 From each photograph, the mean
of the foot process width was calculated as follows: foot process
width¼ p/4 (PGBM length/Pfoot process).
Immunohistochemistry studies
Kidneys were fixed in 4% paraformaldehyde overnight at 4 1C. After
blocking for 20 min with blocking solution (1% bovine serum albumin),
the sections at 4mm were incubated with primary antibodies against
nephrin (N-20; Santa Cruz, CA) and PPAR-a (H-98; Santa Cruz)
overnight at 4 1C, respectively. Sections were examined in a masked
manner on light microscopy (Olympus BX-50; Olympus Optical,
Tokyo, Japan). For quantification of the proportional area of staining, 20
views ( 400 magnification) were randomly located in the glomerulus
of each slide (Scion Image Beta 4.0.2; Scion, Frederick, MD).
Indirect immunofluorescence studies
The indirect immunofluorescence was performed to examine nephrin
expression in the glomeruli. The slides were fixed in ice-cold acetone
for 10 min, subsequently permeabilized with 0.5% Triton X-100 for
15 min, and then blocked with blocking solution (1% bovine serum
albumin) for 30 min. The slides were incubated overnight with rabbit
polyclonal anti-mouse nephrin antibody (kindly supplied by Professor
Karl Tryggvason, Sweden) at 4 1C and then incubated with the fluorescein
isothiocyanate-conjugated anti-rabbit IgG antibody. Images were obtained
by confocal laser-scanning microscopy using a Bio-Rad Radiance 2100
TM confocal system (Philadelphia, PA) attached to a Nikon TE 300
microscope (Tokyo, Japan). A total of 20 glomeruli views per slide
were randomly obtained with a digital camera at  400 magnification.
Cell culture and treatment
Studies involved use of a conditionally immortalized mouse podocyte
cell line as described previously.34 Podocytes were cultured in RPMI-
1640 media (Gibco, Gaithersburg, MD) containing 10% fetal bovine
serum (Hyclone, Logan, UT), 100 U/ml penicillin, and 100mg/ml
streptomycin. Podocytes were propagated in a medium containing
10 U/ml mouse interferon-g (R&D Systems, Minneapolis, MN) at
33 1C. To initiate differentiation, cells were plated in collagen type
I-coated flasks under the nonpermissive condition (37 1C without
interferon-g) for 7–10 days. Podocyte injury was induced by treatment
with 0.5mmol/l DOX for 24 h. To determine the role of PPAR-a in
DOX-induced podocyte injury, fully differentiated podocytes were
preincubated for 6 h with a PPAR-a agonist, fenofibrate (10mmol/l),
before DOX exposure. All cellular experiments were performed a
minimum of three times, unless otherwise indicated.
Analysis of endogenous PPAR-a transcription activity
in cultured podocytes
PPAR-a transcriptional activity was measured as previously described35
using the pTK-(ACO3)-Luc reporter construct containing three
Kidney International (2011) 79, 1302–1311 1309
Y Zhou et al.: PPAR-a and doxorubicin-associated glomerulonephropathy o r ig ina l a r t i c l e
copies of the acetyl-CoA oxidase promoter PPRE. Podocytes
grown in six-well plates were transiently transfected with 5 mg
of reporter construct and 0.5 mg b-galactosidase plasmid as an
internal control using the VigoFect reagent (Vigorous, Beijing,
China) for 48 h. Cells were then incubated with fenofibrate or
vehicle for 6 h, before DOX exposure. Luciferase activity was
measured using a luciferase assay system (Promega, Madison, WI).
Transfection efficiency was normalized to b-galactosidase activity
and expressed as fold induction of vehicle-treated control cells.
Transfection of plasmids did not result in cytotoxicity of podocytes
(Supplementary Figure S17 online).
Detection of apoptosis
The percentage of podocyte apoptosis was measured and quanti-
tated by fluorescence-activated cell sorting. Briefly, cells were grown
to 90% confluency on culture dishes, and treated with fenofibrate
with or without DOX as described above. Cells were then washed
twice with ice-cold phosphate-buffered saline, trypsinized, and
pelleted by centrifugation at 200 g for 5 min. The pellets were washed
once with phosphate-buffered saline, transferred to 5 ml culture
tubes, and resuspended in 2 ml of propidium iodide dye and 2 ml
of Annexin V-fluorescein isothiocyanate (Roche, Indianapolis, IN).
To each tube, 400 ml binding buffer was added. The cells were then
analyzed for apoptosis using FACScalibur (BD Biosciences, San Jose,
CA). Cells positive for Annexin V–fluorescein isothiocyanate and
negative for propidium iodide were deemed apoptotic.
Quantitative RT-PCR
Total RNA was extracted from kidneys and podocytes. For each RNA
sample, 2 mg was reverse-transcribed and resultant cDNA samples
were then used as templates for quantitative PCR. RT-PCR analysis
involved use of SYBR Green (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. Primers designed to target mouse
PPAR-a, nephrin, Bax, Bcl-2, CYP4A10, and CYP4A14 were as fol-
lows: PPAR-a, 50-CGTTCCAGCCCTTCCTCAGTCAGC-30 (sense),
50-GACATCCCGACAGACAGGCACTTG-30 (antisense); nephrin,
50-CCCAACACTGGAAGAGGTGT-30 (sense), 50-CTGGTCGTAGATT
CCCCTTG-30 (antisense); Bax, 50-TGCAGAGGATGATTGCTGAC-30
(sense), 50-GATCAGCTCGGGCACTTTAG-30 (antisense); Bcl-2,
50-AGGAGCAGGTGCCTACAAGA-30 (sense), 50-GCATTTTCCCAC
CACTGTCT-30 (antisense); CYP4A10, 50-GACAAGGACCTACG
TGCTGAGG-30 (sense), 50-CTCATAGCAAATTGTTTCCCA-30 (anti-
sense); CYP4A14, 50-CCCACAGGGACATGCAGATTAG-30 (sense),
50-CACACAGAGCTCGGAAGACC-30 (antisense). The PCR reactions
were carried out at 94 1C for 5 min, followed by 35 cycles of 94 1C for
30 s, 58–62 1C for 30 s and 72 1C for 30 s, with a final extension at
72 1C for 5 min. Actin was used as an internal control.
Western blot analysis of caspase-3
An amount of 40 mg protein samples was transferred to nitrocellu-
lose membrane (Applygen, Beijing, China). The membrane was
washed and blocked in 1 phosphate-buffered saline with 0.02%
Tween-20 supplemented with 5% skim milk powder for 1 h at room
temperature with gentle shaking, and then incubated overnight
(4 1C) with the following primary antibodies: anti-cleaved caspase-3
antibody (Asp 175, Cat no. 9661; Cell Signaling Technology, Boston,
MA) or anti-pro-caspase-3 antibody (Cat no. 9662; Cell Signaling
Technology). The membrane was washed three times for 30 min
in 1 phosphate-buffered saline with 0.02% Tween-20 and
then incubated with horseradish peroxidase-conjugated secondary
antibodies for 1 h at room temperature. After being washed three
times, the membrane was then transferred to the ECL Reagent
(Applygen) and exposed to XBT-1 film (Kodak, Rochester, NY).
Statistical analysis
Data are shown as means±s.e.m. using GraphPad Prism software
(GraphPad Software, La Jolla, CA). Analysis involved analysis of variance
and Student’s t-test. A Po0.05 was considered statistically significant.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation
of China (NSFC) grants 30890041/81030003/30870905/30725033,
the Ministry of Science and Technology (2010CB912503), and the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK RO1 065074-04 & PPG 038226 to YG).
SUPPLEMENTARY MATERIAL
Figure S1. The effect of fenofibrate treatment on proteinuria, plasma
albumin levels, and podocyte foot process effacement in DOX-
treated BALB/c mice.
Figure S2. Measurement of BUN, serum creatinine and urinary KIM-1
levels in DOX-treated BALB/c mice.
Figure S3. Histological examination of the kidneys of DOX-treated
BALB/c mice.
Figure S4. Immunohistochemistry, immunofluorescence and
quantitative real-time PCR analysis of nephrin expression in the
glomeruli of DOX-treated BALB/c mice.
Figure S5. The effect of fenofibrate treatment on proteinuria, plasma
albumin levels, and podocyte foot process effacement in DOX-
treated PPAR-a knockout mice.
Figure S6. Measurement of BUN, serum creatinine and urinary KIM-1
levels in DOX-treated PPAR-a knockout mice.
Figure S7. Renal histology examination in DOX-treated PPAR-a
knockout mice.
Figure S8. Immunohistochemistry, immunofluorescence and
quantitative real-time PCR analysis of nephrin expression in the
glomeruli of DOX-treated PPAR-a knockout mice.
Figure S9. Effect of DOX treatment on expression of PPAR-a in vivo
and vitro.
Figure S10. Ligand-induced transcriptional activity of PPAR-a in
primary PPAR-a gene-deficient mesengial cells (PPAR-a/ MCs).
Figure S11. The protective effect of fenofibrate against DOX-induced
apoptosis in renal glomeruli.
Figure S12. The influence of PPAR-a on DOX-induced ROS
production in podocytes.
Figure S13. The time course of changes in proteinuria, plasma
albumin levels, and podocyte foot process effacement in DOX-
treated 129/SvJ mice.
Figure S14. The time course changes of BUN, serum creatinine and
urinary KIM-1 levels in DOX-treated 129/SvJ mice.
Figure S15. Renal histology examination in DOX-treated 129/SvJ
mice.
Figure S16. Immunohistochemistry, immunofluorescence and
quantitative real-time PCR analysis of nephrin expression in the
glomeruli of DOX-treated mice at different time points.
Figure S17. The condition of podocyte transfected with plasmids for
PPRE-luciferase activity assay.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
1310 Kidney International (2011) 79, 1302–1311
or ig ina l a r t i c l e Y Zhou et al.: PPAR-a and doxorubicin-associated glomerulonephropathy
REFERENCES
1. Cheng H, Wang S, Jo YI et al. Overexpression of cyclooxygenase-2
predisposes to podocyte injury. J Am Soc Nephrol 2007; 18: 551–559.
2. Koshikawa M, Mukoyama M, Mori K et al. Role of p38 mitogen-activated
protein kinase activation in podocyte injury and proteinuria in
experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690–2701.
3. Guo J, Ananthakrishnan R, Qu W et al. RAGE mediates podocyte injury in
adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 2008; 19:
961–972.
4. Vogtlander NP, Tamboer WP, Bakker MA et al. Reactive oxygen
species deglycosilate glomerular alpha-dystroglycan. Kidney Int 2006; 69:
1526–1534.
5. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC et al. Inducible rodent
models of acquired podocyte diseases. Am J Physiol Renal Physiol 2009;
269: F213–229.
6. Guan Y. Peroxisome proliferator-activated receptor family and its
relationship to renal complications of the metabolic syndrome.
J Am Soc Nephrol 2004; 15: 2801–2815.
7. Auboeuf D, Rieusset J, Fajas L et al. Tissue distribution and quantification
of the expression of mRNAs of peroxisome proliferator-activated
receptors and liver X receptor-alpha in humans: no alteration in adipose
tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319–1327.
8. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors
(PPARs): novel therapeutic targets in renal disease. Kidney Int 2001; 60:
14–30.
9. Guan Y, Zhang Y, Davis L et al. Expression of peroxisome proliferator-
activated receptors in urinary tract of rabbits and humans. Am J Physiol
1997; 273: F1013–1022.
10. Portilla D. Energy metabolism and cytotoxicity. Semin Nephrol 2003; 23:
432–438.
11. Duval C, Chinetti G, Trottein F et al. The role of PPARs in atherosclerosis.
Trends Mol Med 2002; 8: 422–430.
12. Park CW, Kim HW, Ko SH et al. Accelerated diabetic nephropathy in mice
lacking the peroxisome proliferator-activated receptor alpha. Diabetes
2006; 55: 885–893.
13. Park CW, Zhang Y, Zhang X et al. PPARalpha agonist fenofibrate improves
diabetic nephropathy in db/db mice. Kidney Int 2006; 69: 1511–1517.
14. Ruan X, Zheng F, Guan Y. PPARs and the kidney in metabolic syndrome.
Am J Physiol Renal Physiol 2008; 294: F1032–F1047.
15. Nagothu KK, Bhatt R, Kaushal GP et al. Fibrate prevents cisplatin-induced
proximal tubule cell death. Kidney Int 2005; 68: 2680–2693.
16. Lin H, Hou CC, Cheng CF et al. Peroxisomal proliferator-activated
receptor-alpha protects renal tubular cells from doxorubicin-induced
apoptosis. Mol Pharmacol 2007; 72: 1238–1245.
17. Li S, Basnakian A, Bhatt R et al. PPAR-alpha ligand ameliorates
acute renal failure by reducing cisplatin-induced increased
expression of renal endonuclease G. Am J Physiol Renal Physiol 2004; 287:
F990–F998.
18. Li S, Wu P, Yarlagadda P et al. PPAR alpha ligand protects during cisplatin-
induced acute renal failure by preventing inhibition of renal FAO and
PDC activity. Am J Physiol Renal Physiol 2004; 286: F572–F580.
19. Li S, Gokden N, Okusa MD et al. Anti-inflammatory effect of fibrate
protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289:
F469–F480.
20. Kamijo Y, Hora K, Kono K et al. PPARalpha protects proximal tubular cells
from acute fatty acid toxicity. J Am Soc Nephrol 2007; 18: 3089–3100.
21. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the
progression of renal disease: a meta-analysis. Kidney Int 2001; 59:
260–269.
22. Kim H, Haluzik M, Asghar Z et al. Peroxisome proliferator-activated
receptor-alpha agonist treatment in a transgenic model of type 2
diabetes reverses the lipotoxic state and improves glucose homeostasis.
Diabetes 2003; 52: 1770–1778.
23. Smulders YM, van Eeden AE, Stehouwer CD et al. Can reduction in
hypertriglyceridaemia slow progression of microalbuminuria in patients
with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997; 27:
997–1002##1997.
24. Negishi K, Noiri E, Maeda R et al. Renal L-type fatty acid-binding protein
mediates the bezafibrate reduction of cisplatin-induced acute kidney
injury. Kidney Int 2008; 73: 1374–1384.
25. Ren S, Xin C, Beck KF et al. PPARalpha activation upregulates nephrin
expression in human embryonic kidney epithelial cells and podocytes by
a dual mechanism. Biochem Biophys Res Commun 2005; 338: 1818–1824.
26. Vielhauer V, Berning E, Eis V et al. CCR1 blockade reduces interstitial
inflammation and fibrosis in mice with glomerulosclerosis and nephrotic
syndrome. Kidney Int 2004; 66: 2264–2278.
27. Wang Y, Wang YP, Tay YC et al. Progressive adriamycin nephropathy in
mice: sequence of histologic and immunohistochemical events. Kidney Int
2000; 58: 1797–1804.
28. Okuda S, Oh Y, Tsuruda H et al. Adriamycin-induced nephropathy as a
model of chronic progressive glomerular disease. Kidney Int 1986; 29:
502–510.
29. Boonsanit D, Kanchanapangka S, Buranakarl C. L-carnitine ameliorates
doxorubicin-induced nephrotic syndrome in rats. Nephrology (Carlton)
2006; 11: 313–320.
30. Zhou Y, Zhang X, Chen L et al. Expression profiling of hepatic genes
associated with lipid metabolism in nephrotic rats. Am J Physiol Renal
Physiol 2008; 295: F662–F671.
31. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity
hypothesis. Nat Rev Nephrol 2009; 5: 713–721.
32. Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol
Hypertens 2010; 19: 393–402.
33. van den Berg JG, van den Bergh Weerman MA, Assmann KJ et al.
Podocyte foot process effacement is not correlated with the level of
proteinuria in human glomerulopathies. Kidney Int 2004; 66: 1901–1906.
34. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the
cytoskeleton and cell contacts induce process formation during
differentiation of conditionally immortalized mouse podocyte cell lines.
Exp Cell Res 1997; 236: 248–258.
35. Zheng F, Fornoni A, Elliot SJ et al. Upregulation of type I collagen by
TGF-beta in mesangial cells is blocked by PPARgamma activation.
Am J Physiol Renal Physiol 2002; 282: F639–F648.
Kidney International (2011) 79, 1302–1311 1311
Y Zhou et al.: PPAR-a and doxorubicin-associated glomerulonephropathy o r ig ina l a r t i c l e
